sofidexFor patientsAre you a clinician? Clinical site
Ask Sofi
Listen
Patient SupportEmergencies & Reporting
Log inSign up

Meds & supplements  ›  Ensartinib

Medicine

Ensartinib

ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)as detected by an FDA-approved test who have not previously received…

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test who have not previously received an ALK-inhibitor.
  • ( 1, 2.1 )
Do not take if
  • ENSACOVE is contraindicated in patients who have experienced a severe hypersensitivity reaction to ENSACOVE, FD&C Yellow No.
  • 5 (tartrazine), or to any of its components.

What it is used for

ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)as detected by an FDA-approved test who have not previously received an ALK-inhibitor.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Interstitial Lung Disease/Pneumonitis
  • Hepatoxicity
  • Dermatologic Adverse Reactions
  • Bradycardia
  • Hyperglycemia
  • Visual Disturbances
  • Increased Creatine Phosphokinase
  • Hyperuricemia
  • FD&C Yellow No. 5 (Tartrazine)

Who should not take it

ENSACOVE is contraindicated in patients who have experienced a severe hypersensitivity reaction to ENSACOVE, FD&C Yellow No. 5 (tartrazine), or to any of its components.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Ensartinib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/ensartinib

APA 7th

sofidex. (2026, August 2). Ensartinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/ensartinib

AMA 11th

Ensartinib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/ensartinib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.